von Nils Nicholas Hecht ; Daisy Haddad ; Konrad Neumann ; Leonie Schumm ; Nora Dengler ; Lars Wessels ; Patrick Dömer ; Simeon Helgers ; Franziska Meinert ; Sebastian Major ; Coline L. Lemale ; Jens P. Dreier ; Peter Vajkoczy ; Johannes Woitzik
von Kiarash Ferdowssian ; Julien Haemmerli ; Lars Wessels ; Robert Mertens ; Claudius Jelgersma ; Simon H. Bayerl ; Ulf C. Schneider ; Johannes Woitzik ; Katharina Faust ; Nils Hecht ; Marcus Czabanka ; Hans-Christian Bauknecht ; Peter Vajkoczy
von Jens P. Dreier ; Coline L. Lemale ; Viktor Horst ; Sebastian Major ; Vasilis Kola ; Karl Schoknecht ; Michael Lothar Scheeler ; Jed A. Hartings ; Peter Vajkoczy ; Stefan Wolf ; Johannes Woitzik ; Nils Nicholas Hecht
von Maja Krech ; Amos Muench ; Daniel Teichmann ; Peter Kuzman ; Abigail Kora Suwala ; Franziska M. Ippen ; Michael Müther ; Katharina J. Weber ; Katharina Wenger-Alakmeh ; Julia Onken ; Peter Vajkoczy ; Felix Behling ; Sven-Axel May ; Georgios Ntoulias ; Joachim K. Krauss ; Oday Atallah ; Majid Esmaeilzadeh ; Wolf C. Mueller ; Frank L. Heppner ; Helena Radbruch ; Carsten Dittmayer ; Werner Stenzel ; Arend Koch ; David Capper ; David Kaul ; Werner Paulus ; Karl Plate ; Joachim P. Steinbach ; Markus Czabanka ; Rudi Beschorner ; Andreas von Deimling ; Michael Bockmayr ; Julia E. Neumann ; Sebastian Brandner ; Teresa Krieger ; Christian Hartmann ; Christian Thomas ; Leonille Schweizer
Veröffentlicht: 11. Juni 2025 ; Gesehen am 29.10.2025
DNA methylation profiling; FGFR3; Neurocytoma; Progression-free survival; Radiotherapy
Central neurocytomas (CN) are intraventricular brain tumors predominantly occurring in young adults. Although prognosis is usually favorable, tumor recurrence is common, particularly following subtotal resection (STR). Currently, the risk of progression is evaluated using atypical features and an elevated Ki67 proliferation index. However, these markers lack consistent definitions, raising the need for objective criteria. Genome-wide DNA methylation profiles were examined in 136 tumors histologically classified as CN. Clinical/histopathological characteristics were assessed in 93/90 cases, and whole-exome sequencing was conducted in 12 cases. Clinical and molecular characteristics were integrated into a survival model to predict progression-free survival (PFS). A diagnosis of CN was epigenetically confirmed in 125 of 136 cases (92%). No DNA methylation subgroups were identified, but global DNA hypomethylation emerged as a hallmark feature of CN associated with higher recurrence risk. Risk stratification based on histological features of atypia and Ki67 proliferation index was not reproducible across neuropathologists. Hypomethylation at the FGFR3 locus, accompanied by increased FGFR3 protein expression, was observed in 97% of cases. Gross total resection was associated with significantly improved PFS compared to STR, while patients undergoing STR receiving radiotherapy had a better outcome (p = 0.0001). Younger patients were identified as having a higher risk of recurrence (p = 0.026). Patient age and treatment strategy were key factors associated with survival outcomes in this cohort. These findings underscore the importance of closer follow-up for younger patients and radiotherapy for STR cases. Furthermore, FGFR3 represents a hallmark feature and potential therapeutic target, warranting further investigation.
Acta neuropathologica Berlin : Springer, 1961 149(2025), Artikel-ID 61, Seite 1-16 Online-Ressource
von Aline M. Grimm ; Felix Borngässer ; Fran Ganz-Lord ; Annika Bald ; Peter Shamamian ; Michael E. Kiyatkin ; Maíra Isabella Rudolph ; Greta M. Eikermann ; Ankeeta Shukla ; Ling Zhang ; Simon Schäfer ; Maximilian Schaefer ; Sophia Riesemann ; Annika Eyth ; Pooja Kumar ; Matthias Eikermann ; Alex C. Spyropoulos ; Christopher Tam ; Ibraheem M. Karaye
von Jacob Hamm ; Alzbeta Busana ; Ahmad Amanzada ; Alexander Arlt ; Thomas Asendorf ; Samantha Carswell ; Ulrike Denzer ; Louis Elsing ; Fabian Frost ; Lucia Guilabert ; Karim Hamesch ; Marcus Hollenbach ; Péter Hegyi ; Alexander Kleger ; Jan Krivinka ; Lumir Kunovsky ; Christian Meinhardt ; Veit Phillip ; Sophie Schlosser-Hupf ; Simon Sirtl ; Lukas Welsch ; Julian Cardinal von Widdern ; Albrecht Neesse ; Christoph Ammer-Herrmenau ; Patrick Michl
PROTOCOL working Group: Georg Beyer, Patrick Michl [und viele weitere] ; Gesehen am 17.12.2025
Lumen-apposing metal stents (LAMS) are widely used to drain walled-off necrosis (WON). LAMS occlusion is a significant clinical problem and identification of risk factors for LAMS occlusion could contribute to novel preventive strategies. A previous study suggested contradictory effects of proton pump inhibitors (PPIs) on occlusion and necrosectomy rates.
Seite 6 von 301
